|
 |
|
|||||||
|
|||||||||
Diabetes 54:1164-1170, 2005
© 2005 by the American Diabetes Association, Inc.
Inhalation of Insulin (Exubera) Is Associated With Augmented Disposal of Portally Infused Glucose in Dogs
1 Vanderbilt University Medical Center, Nashville, Tennessee
2 Lovelace Respiratory Research Institute, Albuquerque, New Mexico
3 Aventis Pharmaceuticals, Bridgewater, New Jersey
4 Pfizer, New York, New York
The results of the present study, using the conscious beagle dog, demonstrate that inhaled insulin (INH; Exubera) provides better glycemic control during an intraportal glucose load than identical insulin levels induced by insulin (Humulin) infusion into the inferior vena cava (IVC). In the INH group (n = 13), portal glucose infusion caused arterial plasma glucose to rise transiently (152 ± 9 mg/dl), before it returned to baseline (65 min) for the next 2 h. Net hepatic glucose uptake was minimal, whereas nonhepatic uptake rose to 12.5 ± 0.5 mg · kg–1 · min–1 (65 min). In the IVC group (n = 9), arterial glucose rose rapidly (172 ± 6 mg/dl) and transiently fell to 135 ± 13 mg/dl (65 min) before returning to 165 ± 15 mg/dl (125 min). Plasma glucose excursions and hepatic glucose uptake were much greater in the IVC group, whereas nonhepatic uptake was markedly less (8.6 ± 0.9 mg · kg–1 · min–1; 65 min). Insulin kinetics and areas under the curve were identical in both groups. These data suggest that inhalation of Exubera results in a unique action on nonhepatic glucose clearance.
Address correspondence and reprint requests to Dale S. Edgerton, PhD, Molecular Physiology and Biophysics, Vanderbilt University Medical Center, 710 Robinson Research Bldg., Nashville, TN 37232-0615. E-mail: dale.edgerton{at}vanderbilt.edu
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  P. A. Hollander, A. Krasner, S. Klioze, P. Schwartz, and W. Duggan Body Weight Changes Associated With Insulin Therapy: A retrospective pooled analysis of inhaled human insulin (Exubera) versus subcutaneous insulin in five controlled Phase III trials Diabetes Care, October 1, 2007; 30(10): 2508 - 2510. [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Edgerton, K. M. Stettler, D. W. Neal, M. Scott, L. Bowen, W. Wilson, C. H. Hobbs, C. Leach, T. R. Strack, and A. D. Cherrington Inhalation of Human Insulin Is Associated with Improved Insulin Action Compared with Subcutaneous Injection and Endogenous Secretion in Dogs J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1258 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Edgerton, A. D. Cherrington, P. Williams, D. W. Neal, M. Scott, L. Bowen, W. Wilson, C. H. Hobbs, C. Leach, M.-c. Kuo, et al. Inhalation of Human Insulin (Exubera) Augments the Efficiency of Muscle Glucose Uptake In Vivo Diabetes, December 1, 2006; 55(12): 3604 - 3610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Morton-Eggleston and E. J Barrett Inhaled insulin. BMJ, May 6, 2006; 332(7549): 1043 - 1044. [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Insulin Treatment and Type 1 Diabetes Topics Diabetes Care, April 1, 2006; 29(4): 936 - 944. [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. DiCostanzo, D. P. Dardevet, D. W. Neal, M. Lautz, E. Allen, W. Snead, and A. D. Cherrington Role of the hepatic sympathetic nerves in the regulation of net hepatic glucose uptake and the mediation of the portal glucose signal Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E9 - E16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Skyler, R. S. Weinstock, P. Raskin, J.-F. Yale, E. Barrett, J. E. Gerich, H. C. Gerstein, and the Inhaled Insulin Phase III Type 1 Diabetes Stud Use of Inhaled Insulin in a Basal/Bolus Insulin Regimen in Type 1 Diabetic Subjects: A 6-month, randomized, comparative trial Diabetes Care, July 1, 2005; 28(7): 1630 - 1635. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |